PROSCA/BLADDR 2023 | Challenges in classifying bladder tumors: insights on heterogeneity and precision

Eva Compérat, MD, PhD, from the Medical University of Vienna, discusses challenges in classifying bladder tumors. While there’s ongoing research on molecular classifications, pathology doesn’t universally recommend them due to a lack of clear data. Prof. Compérat emphasizes difficulties in testing all tumors for alterations and the importance of recognizing specific subtypes, like FGFR-altered tumors, for targeted treatments. The heterogeneity of cancer poses challenges, especially in tumors with varying subtypes. Liquid biopsies are gaining attention, but standardization is lacking. Collaborative efforts to share molecular results can enhance precision. Despite advancements, challenges persist in staging, grading, and molecular classification. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and protected by global copyright laws. All rights are reserved.